

U.S.S.N. 09/445,865  
Filed: February 11, 2000  
**AMENDMENT AND RESPONSE TO OFFICE ACTION**

**In the Claims**

1-28 canceled.

29. (currently amended) A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a cytotoxic drug by the action of NQO2 and an analogue of nicotinamide riboside (reduced) (NRH) having formula I: which can pass reducing equivalents to NQO2, wherein the prodrug is CB 1954, and wherein R1 is the analogue of nicotinamide riboside (reduced) (NRH) is 1-(carboxamidomethyl) dihydronicotinamide selected from the group consisting of: substituted alkyl, including substitution by CONH<sub>2</sub>, OH, halogen, CN and COOH; alkyl; aryl; substituted aryl; CONR<sup>a</sup>R<sup>b</sup>, where R<sup>a</sup> and R<sup>b</sup> are independently H, alkyl, or substituted alkyl, and R<sup>2</sup> and R<sup>3</sup> are independently H, alkyl, or substituted alkyl and R<sup>4</sup> is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH<sub>2</sub>, or OH.

30. canceled.

31. (previously presented) The method of claim 29 wherein the analogue of NRH is able to permeate the target cell membrane.

32. (previously presented) The method of claim 29 wherein the target cell is a tumour.

33. (previously presented) The method of claim 29, the method further comprising determining, before administering the prodrug and analogue of NRH, whether the target cell to be treated expresses NQO2.

34-39 canceled.

U.S.S.N. 09/445,865

Filed: February 11, 2000

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

40. (original) The method of claim 29 wherein the patient has cancer.

41-44 canceled.